AKT1 and melanoma: They also found that mTOR nonsynonymous mutations were significantly associated with poor survival in patients with melanoma, suggesting that PI3K-AKT-mTOR pathway inhibitors may represent a promising treatment strategy for patients with mTOR-mutant melanoma (48).